Concepedia

Publication | Open Access

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

DOIFull Paper Access

211

Citations

20

References

2009

Year

Hagop M. Kantarjian, Ricardo Pasqüini, Vincent Lévy, Saengsuree Jootar, Jerzy Hołowiecki, Nelson Hamerschlak, Timothy P. Hughes, Eric Bleickardt, David Dejardin, Jörge E. Cortes,
Cancer

Abstract

After 2 years of follow-up, dasatinib demonstrated durable responses and improved response and progression-free survival rates relative to high-dose imatinib.

References

YearCitations

Page 1